Progenics Pharmaceuticals Inc. (PGNX) Drops 8.91% on January 11

Equities Staff |

Progenics Pharmaceuticals Inc. (PGNX) was one of the Russell 2000's biggest losers for Monday January 11 as the stock slid 8.91% to $4.50, a loss of $-0.44 per share. Starting at an opening price of $4.95 a share, the stock traded between $4.49 and $5.34 over the course of the trading day. Volume was 1.04 million shares over 7,762 trades, against an average daily volume of 979,008 shares and a total float of 69.81 million.

The losses send Progenics Pharmaceuticals Inc. down to a market cap of $314.12 million. In the last year, Progenics Pharmaceuticals Inc. has traded between $11.15 and $4.86, and its 50-day SMA is currently $6.54 and 200-day SMA is $6.71.

Progenics Pharmaceuticals Inc is engaged in the development of medicines for oncology. The Company develops products for the treatment of prostate cancer, opioid-induced constipation, or OIC, as well as OIC for non-cancer pain.

Progenics Pharmaceuticals Inc. is based out of Tarrytown, NY and has some 57 employees. Its CEO is Mark R. Baker.

For a complete fundamental analysis analysis of Progenics Pharmaceuticals Inc., check out’s Stock Valuation Analysis report for PGNX. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

International Western Petroleum Inc

International Western Petroleum Inc is an exploration-stage oil and natural gas company. The Company is engaged in the acquisition, development, and exploration of crude oil and natural gas properties in…

Private Markets

BioSculpture Technology, Inc.

BioSculpture Technology, Inc. (“BST”) is a commercial-stage medical device manufacturer of liposuction surgical instruments for surgeons. It offers the FDA-cleared Twin Cannula Assisted Liposuction ("TCAL") Airbrush Liposculptor II® controllers, Airbrush®…

Ozobot by Evollve Inc

Ozobot is a world leader in compact super intelligent robots that entertain and educate through fun interactive gaming.